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Introduction: The use of human umbilical cord Wharton Jelly-derived mesenchymal stem cells (hWJ-MSCs) has
been considered a new potential source for future safe applications in regenerative medicine. Indeed, the application
of hWJ-MSCs into different animal models of disease, including those from the central nervous system, has shown
remarkable therapeutic benefits mostly associated with their secretome. Conventionally, hWJ-MSCs are cultured and
characterized under normoxic conditions (21 % oxygen tension), although the oxygen levels within tissues are
typically much lower (hypoxic) than these standard culture conditions. Therefore, oxygen tension represents an
important environmental factor that may affect the performance of mesenchymal stem cells in vivo. However, the
impact of hypoxic conditions on distinct mesenchymal stem cell characteristics, such as the secretome, still
remains unclear.
Methods: In the present study, we have examined the effects of normoxic (21 % O2) and hypoxic (5 % O2)
conditions on the hWJ-MSC secretome. Subsequently, we address the impact of the distinct secretome in the
neuronal cell survival and differentiation of human neural progenitor cells.
Results: The present data indicate that the hWJ-MSC secretome collected from normoxic and hypoxic conditions
displayed similar effects in supporting neuronal differentiation of human neural progenitor cells in vitro. However,
proteomic analysis revealed that the use of hypoxic preconditioning led to the upregulation of several proteins
within the hWJ-MSC secretome.
Conclusions: Our results suggest that the optimization of parameters such as hypoxia may lead to the development
of strategies that enhance the therapeutic effects of the secretome for future regenerative medicine studies and
applications.Introduction
The use of adult stem cells, including human mesenchy-
mal stem cells (hMSCs), as a possible therapeutic tool in
the regenerative medicine field has been widely assessed
[1–3], and has emerged as a promising therapeutic
approach [4–6]. The stem/progenitor cells present in the
human Wharton Jelly of the umbilical cord, known as
human Wharton Jelly mesenchymal stem cells (hWJ-* Correspondence: asalgado@ecsaude.uminho.pt
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article, unless otherwise stated.MSCs), have been suggested as a possible population of
interest for future clinical applications [7–9]. Like bone
marrow MSCs or adipose stem cells, these populations
are also defined as MSCs [10–12]. The secretion of
trophic bioactive molecules (i.e. MSC secretome) has
now been considered as a critical element for their
therapeutic efficacy [13–16]. Indeed, over the last dec-
ade, there has been a substantial effort to assess the
impact of MSCs (including hWJ-MSCs) and their secre-
tome into different disorders, such as those affecting the
central nervous system (CNS) [14]. However, despite
promising results for hMSCs and their paracrine activity,
the low number of cells that are normally obtained after
isolation continues to be a limitation for theirle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing strategy to overcome this limitation is to focus on
the modulation of culture conditions in which the dis-
solved oxygen concentration may play an important role
in the behavior of MSCs [17].
Usually, hMSCs are cultured in vitro in static culture
and in a 21 % oxygen tension environment. However,
studies have demonstrated that the physiological niches
from where hMSCs are isolated in the human body are
at much lower oxygen tensions than 21 % [20–22]. In-
deed, depending of the environmental niche from where
MSCs are isolated, oxygen tension can vary between 1
and 7 % in the bone marrow, and between 10 and 15 %
in the adipose tissue [23–25]. Regarding birth-associated
tissues such as the umbilical cord, the oxygen tension
within the mammalian female reproductive tract was
shown to be low, between 1.5 and 8 %, and lasts
throughout the fetal development with a dissolved oxy-
gen tension in the fetal circulation rarely exceeding 5 %
[26, 27]. Even though consensus values of 3 to 5 % of
oxygen in tissues are generally accepted, the actual oxy-
gen concentration in situ strongly depends on the
vascularization of the tissue and its metabolic activity
[28, 29]. In line with this, studies have shown that hyp-
oxic culture conditions affect the therapeutic properties
of hMSCs [30, 31]. For instance, Rhijn and colleagues
[17] demonstrated that hypoxic preconditioning en-
hances the regenerative potential of MSCs, maintaining
their immunosuppressive capacities under these condi-
tions. In addition, Tsai and colleagues [30] demonstrated
that the use of 1 % oxygen reduces hMSC senescence
while it increases their proliferation levels and maintains
their differentiation properties. Similar outcomes were
also described for hMSCs obtained from adipose tissue
and Wharton Jelly [20, 32, 33]. Furthermore, in the
secretome the oxygen tension seems to play an import-
ant role [34, 35]. Previous studies have shown that by
changing the oxygen concentration it was possible to
modulate the angiogenic potential of MSCs through the
increase in the secretion of vascular endothelial growth
factor (VEGF), beta-fibroblast growth factor (bFGF) and
hepatocyte growth factor (HGF) [34–36]. Regarding hyp-
oxic conditions, Volkmer and colleagues [37] observed
that prolonged exposure to hypoxia leads to cell death.
On the other hand, under normoxic conditions, studies
have shown that higher levels of oxygen could be toxic,
causing oxidative stress due to the generation of reactive
oxygen species (ROS) which could alter the metabolic
efficiency of the cells [21, 29]. Nevertheless, the real im-
pact of oxygen on key hMSC characteristics is still un-
clear. Additionally, it has been shown that hMSCs
respond to changes in their physiological environment
[38], namely by using dynamic culturing environments
such as those provided by bioreactors [38–40]. Indeed,previous work from our group demonstrated that, using
stirred suspension bioreactors, a number of advantages
can be achieved including: (1) a large number of cells
can be expanded in one vessel (minimizing vessel-to-
vessel variability and minimizing cost related to labor
and consumables); (2) the bioreactors can be operated in
a fed-batch or perfusion mode of operation; and (3) the
bioreactors can be set up with computer-controlled on-
line monitoring instruments to ensure tight control of
process variables such as pH, temperature and dissolved
oxygen concentration.
Thus, in the present work we aimed to characterize
and analyze the effects of the hWJ-MSC secretome col-
lected from hypoxic culture conditions and compare
that to those obtained from normoxic culturing condi-
tions. Results revealed that the use of different oxygen
conditions (i.e., hypoxic and normoxic) led to a different
secretome profile for hWJ-MSCs. In line with this, we
further observed that hWJ-MSCs were able to secrete
important neuroregulatory molecules such as glia-
derived nexin (GDN) and cystatin C (Cys C), which
were upregulated under the normoxic condition. In the
hypoxic condition, the proteins thymosin-beta, elong-
ation factor 2 (EF-2), ubiquitin carboxy-terminal hydro-
lase L1 (UCHL1), clusterin, peroxiredoxin-1 (Prx1) and
14-3-3, were found to be upregulated in the hWJ-MSC
secretome. Additionally, we have also found vitronectin,
cadherin-2 and multidrug resistance-associated protein
1 (MRP1) were expressed only in the normoxic condi-
tions, while pigment epithelium-derived factor (PEDF),
insulin growth factor 2 (IGF-2), semaphorin-7A, macro-
phage migration inhibitory factor (MIF), heat shock pro-
tein 70 kDa (Hsp70) and moesin were only found to be
present in the hypoxic conditions. Finally, we also ob-
served that the obtained secretomes were able to induce
and support neuronal differentiation of human telenceph-
alon neural precursor cells (hNPCs) in vitro, where the
previously identified proteins in the hWJ-MSC condi-
tioned medium (CM) may explain our results.
Methods
Expansion of hWJ-MSCs under hypoxic and normoxic
conditions (in dynamic bioreactors) and collection of CM
Preparation of 500 mL suspension bioreactors
A DASGIP Parallel Bioreactor system (DASGIP, Julich,
Germany) was used for the expansion of hWJ-MSCs in
dynamic conditions. Prior to inoculating hWJ-MSCs in
the DASGIP bioreactors, the 500 mL suspension biore-
actors (containing modified Teflon 4-paddle impellers)
were siliconized using Sigmacote (Sigma, St. Louis, MO,
USA) to minimize cell attachment to the sides of the
bioreactor vessel and the impeller. After siliconization
and autoclaving of the vessels, the DASGIP system was
calibrated according to procedures provided by the
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37 °C using a heating jacket; (2) 100 % dissolved oxygen
(corresponding to oxygen saturation of the medium at
37 °C exposed to 21 % O2 in the headspace) for nor-
moxic conditions; (3) 21 % dissolved oxygen (corre-
sponding to oxygen saturation of the medium at 37 °C
exposed to 5 % O2 in the headspace) for hypoxic condi-
tions; (4) pH of 7.4, controlled by a gas mixture
connected to oxygen, nitrogen, carbon dioxide and air
tanks that was introduced into the headspace; and (5)
agitation of 52 rpm using a magnetic stir plate under the
bioreactors.
Preparation of microcarriers and inoculation of hWJ-MSCs
Cytodex 3 microcarriers (GE Healthcare, Uppsala,
Sweden) were used for this study and were prepared as
follows: 1.0 g (per condition) of microcarriers were
weighed out and hydrated in 50 mL 1×phosphate-
buffered saline (PBS; Life Technologies, Paisley, UK) in
two 125 mL, pre-siliconized, Erlenmeyer flasks, at room
temperature overnight. To this flask, 2–3 drops of
Tween 80 (United States Biochemical Corporation,
Cleveland, OH, USA) were added to break the surface
tension and ensure proper wetting and sedimentation of
the microcarriers. The microcarriers were then washed
three time with 1×PBS, and autoclaved. Following
autoclaving, the microcarriers were incubated with
fetal bovine serum (FBS; Life Technologies, Paisley,
UK) for 6 h at 37 °C to coat the microcarriers with
serum-attachment factors, and agitated every 30 min.
After 6 h, the FBS was removed, the microcarriers
were washed twice with our serum-free medium
(PPRF-msc6), and then inoculated into our 500 mL
DASGIP bioreactors in 275 mL of serum-free medium
for 4 h at the controlled culture conditions. The
hWJ-MSCs were first expanded in Nunc T-flasks
(Thermo Scientific, Waltham, MA, USA) pre-coated
with a 0.1 % gelatin solution. The gelatin solution was
prepared by adding 0.1 g of Type B bovine gelatin (Sigma,
St. Louis, MO, USA) to 100 mL of cell culture water
(Lonza, Walkersville, MD, USA). This was then autoclaved
to both sterilize the solution and dissolve the gelatin.
After autoclaving, the gelatin was then cooled in the
4 °C fridge overnight. T75 T-flasks were coated with
gelatin by: 1) adding 4 mL of gelatin to the flask and
letting it sit for 30 min, 2) then removing the gelatin
from the flask, and 3) allowing the flask to dry over-
night before use. After this, cryopreserved hWJ-MSCs
at passage 2 (P2), and derived from three donors (WJ1,
WJ2, and WJ3) were expanded in serum-free medium
(PPRF-msc6 [41]) in static culture for two passages
before inoculation into the DASGIP bioreactors. The
cells were harvested using trypsin-EDTA, and then in-
oculated into the bioreactors at a density of 24,000cells/mL (based on the final volume of 500 mL) and the
volume of the bioreactors was maintained at 325 mL
for the first 24 h to increase cell attachment. After 24 h
the culture volume was increased to 500 mL to bring
the final microcarrier density to 2.0 g/L. The cells were
cultured on the microcarriers for 72 h, after which time
the bioreactors were removed from the DASGIP sys-
tem, and placed in a biosafety cabinet for 10 min to
allow the microcarriers to settle. The supernatant was
removed from the bioreactors, and the microcarriers
were washed once with 100 mL of Neurobasal®-A
medium (Life Technologies). Following this, 500 mL of
Neurobasal®-A medium with 1 % of kanamycin (Life
Technologies) were added to the bioreactors and the
bioreactors were placed back into the DASGIP control
system for 24 h. After 24 h, the bioreactors were again
removed from the system, placed in a biosafety cabinet
for 10 min to allow the microcarriers to settle, the
supernatant was harvested and centrifuged at 300 g for
10 min to remove any cell debris. This supernatant
(called the dynamic CM) collected from normoxic and
hypoxic conditions was then stored at −80 °C until it
was required for further experiments.Growth of hNPCs and incubation with hWJ-MSC CM
collected from normoxic and hypoxic conditions
hNPCs were isolated from the telencephalon region of a
10-week postconception (gestational age) fetus using the
protocols developed at the Queen Elizabeth II Health
Sciences Centre under strict ethical guidelines [42–44];
ethical consent was approved by the Conjoint Health Re-
search Ethics Board (CHREB), University of Calgary
(ID: E-18786). Pre-isolated and cryopreserved hNPCs
were thawed at 37 °C and the contents placed into a
Nunc T-25 flask (Thermo Scientific) containing 5 mL
of a serum-free medium PPRF-h2 [42]. After 2 days,
the cells were harvested and mechanically dissociated
into a single cell suspension, and subcultured into fresh
cell growth medium (PPRF-h2). Every 4 days, the T
flasks were fed by replacing 40 % of the spent medium
with fresh growth medium. After 14–20 days of growth
in the culture flasks, hNPCs were passaged and plated onto
pre-coated (poly-D-lysine hydrobromide (100 μg/mL) and
laminin (10 μg/mL); Sigma) 24-well plates at a density
of 4.0×104 cells per well in the presence of the hWJ-
MSC CM obtained from either hypoxic or normoxic
conditions. Neurobasal-A medium (Life Technologies)
with 1 % of kanamycin (Life Technologies) was used as
control, without the addition of any kind of exogenous
cocktail of factors, as already described by our research
group [45, 46]. The plates were placed in an incubator
operating at 37 °C, 5 % CO2, 95 % air and 90 % relative
humidity for 5 days.
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hNPCs were fixed in 4 % paraformaldehyde (Mallinckrodt,
Paris, KY, USA) for 15 min, and then permeabilized by
incubation with 0.1 % Triton X-100 (Sigma) in 1×PBS for
5 min at room temperature, and washed three times in
1×PBS. hNPCs were then blocked with 10 % fetal calf
serum (FCS; Life Technologies) in 1×PBS, followed by a
1-h incubation (at 37 °C) with the primary antibodies:
rabbit anti-doublecortin (DCX; 1:500, Abcam, Cambridge,
MA, USA) to detect immature neurons and mouse anti-
rat microtubule associated protein-2 (MAP-2; 1:500,
Sigma) to detect mature neurons. hNPCs were then
washed with 1×PBS three times and incubated with the
secondary antibodies: Alexa Fluor 488 goat anti-rabbit
(Life Technologies) and Alexa Fluor 594 goat anti-
mouse immunoglobulin G (IgG; Life Technologies) for
1.0 h at 37 °C and then 10 min with 4-6-diamidino-2-phe-
nylindole-dihydrochloride (DAPI; Life Technologies).
After staining, samples were observed under an Olympus
BX-61 Fluorescence Microscope (Olympus, Hamburg,
Germany). For quantification purposes, cell counts were
performed under blind observation by using Cell-P soft-
ware (Olympus). For this, three cover slips and ten repre-
sentative fields per condition were chosen and analyzed.
In order to normalize the data between the different sets,
the results are presented in percentage of cells. This was
calculated by counting the cells positive for MAP-2/DCX
markers and dividing this value by the total number of
cells/field (DAPI-positive cells; n = 3).
Proteomics – mass spectrometry and SWATH acquisition
Liquid digestion/sample preparation
hWJ-MSC CM was firstly concentrated using a Vivaspin
20 sample concentrator (5 kDa; GE Healthcare) by ultra-
centrifugation at 3000 g for 45 min. Then, the CM was
precipitated with Trichloroacetic acid (TCA)–acetone.
TCA was added to each sample to a final concentration
of 20 % (v/v), followed by 30 min incubation at −80 °C
and centrifugation at 20,000 g for 20 min. Protein pellets
were washed with ice-cold (−20 °C) acetone, briefly the
pellets were solubilised in acetone, aided by ultrasonica-
tion, followed by a centrifugation at 20,000 g for 20 min.
The washed pellets were resuspended in 1.0 M triethy-
lammonium bicarbonate buffer (TEAB; Sigma), aided by
ultrasonication, followed by a centrifugation at 20,000 g
for 5.0 min to remove insoluble material [47].
Samples were quantified using the 2D-Quant Kit (GE
Healthcare) and 100 μg of each sample were subjected to
liquid digestion. Briefly, 4 μL of 50 mM tris (2-carbox-
yethyl)phosphine (TCEP) was added to 45 μL of sample,
followed by an ultrasonication step for 2 min. Next, 2 μL
of 600 mM methyl methathiosulfonate (MMTS) was
added and samples were left to react for 10 min at room
temperature. TEAB was then added to adjust the volumeof sample to 100 μL, and the samples were digested with
trypsin overnight (2 μg trypsin/sample) at 37 °C, with
swirling at 650 rpm. Reactions were stopped by the
addition of 2 μL formic acid (FA) and the peptides were
dried by rotary evaporation under vacuum. Before di-
gestion, the samples were spiked with 2 μg green fluor-
escent protein (GFP) to monitor samples loss during
the procedure.
Before performing the tandem mass spectrometry
(MS/MS) analysis the peptide mixtures were cleaned/
desalted using OMIX tips with C18 stationary phase
(Agilent Technologies, Santa Clara, CA, USA) as recom-
mended by the manufacturer. Eluates, spiked with iRT
peptides (Biognosys, Zürich, Switzerland), were dried by
rotator evaporation, avoiding totally evaporating the
samples. The samples were resuspended to 23 μL in a
solution of 2 % acetonitrile (ACN) and 0.1 % FA
followed by vortex, spin and sonication in a water bath
for 2 min with pulses of 1.0 s (1.0 s sonication followed
by a 1.0 s break pulse), at 20 % intensity, in a sonicator
VibraCell 750 W, Sonics® (Sonics&Materials, Stowmarket,
UK). In order to remove insoluble material the peptide
mixture was then centrifuged for 5 min at 14,000 g and
collected into the proper vial for liquid chromatography-
mass spectrometry (LC/MS) injection.
SWATH acquisition
Samples were analyzed on a Triple TOF™ 5600 System
(ABSciex, Framingham, MA, USA) in two phases:
information-dependent acquisition (IDA) was followed
by SWATH (Sequential Windowed data independent
Acquisition of the Total High-resolution Mass Spectra)
acquisition on the same sample [48]. Peptides were re-
solved by liquid chromatography (nanoLC Ultra 2D,
Eksigent, California, USA) on a ChromXP™ C18AR re-
verse phase column (300 μm ID × 15 cm length, 3 μm
particles, 120 Å pore size; Eksigent) at 5 μL/min. Pep-
tides were eluted into the mass spectrometer with an
ACN gradient in 0.1 % FA (2 % to 35 % ACN, in a linear
gradient for 25 min), using an electrospray ionization
source (DuoSpray™ Source, ABSciex).
For IDA, the mass spectrometer was set to scanning
full spectra (350–1250 m/z) for 250 ms, followed by up
to 30 MS/MS scans (100–1500 m/z for 75 ms each).
Candidate ions with a charge state between +2 and +5
and counts above a minimum threshold of 70 counts/s
were isolated for fragmentation and one MS/MS spectra
was collected for 75 ms before adding those ions to the
exclusion list for 15 s (mass spectrometer operated by
Analyst® TF 1.6, ABSciex). Rolling collision was used
with a collision energy spread of 5. Peptide identifica-
tion was performed with Protein Pilot software (v4.5,
ABSciex). Search parameters used were the following:
SwissProt database, against a database composed of
Teixeira et al. Stem Cell Research & Therapy  (2015) 6:133 Page 5 of 14human and bovine species from SwissProt database (re-
lease at February 2014), GFP and iRT peptides, and
using MMTS alkylated cysteines as fixed modification.
An independent false discovery rate (FDR) analysis
using the target-decoy approach provided with the Pro-
tein Pilot software was used to assess the quality of the
identifications, and positive identifications were con-
sidered when identified proteins and peptides reached a
5 % local FDR [49, 50].
The SWATH setup was essentially that used by Gillet
et al. [51], with the same chromatographic conditions
used as in the IDA run described above. For SWATH-
MS based experiments, the mass spectrometer was op-
erated in a looped product ion mode. The instrument
was specifically tuned to allow a quadruple resolution
of 25 m/z mass selection. Using an isolation width of
26 m/z (containing 1 m/z for the window overlap), a
set of 30 overlapping windows was constructed cover-
ing the precursor mass range of 350–1100 m/z. A 250
ms survey scan (350–1500 m/z) was acquired at the be-
ginning of each cycle for instrument calibration and
SWATH MS/MS spectra were collected from 100–1500
m/z for 90 ms resulting in a cycle time of 3 s from the
precursors ranging from 350 to 1100 m/z. The collision
energy for each window was determined according to
the calculation for a charge +2 ion centered upon the
window with a collision energy spread of 15.
A specific library of precursor masses and fragment
ions was created by combining all files from the IDA ex-
periments, and used for subsequent SWATH processing.
Libraries were obtained using Protein Pilot™ software
(v4.5, ABSciex) with the same parameters as described
above. Data processing was performed using SWATH™
processing plug-in for PeakView™ (v2.0.01, ABSciex);
briefly peptides were selected automatically from the li-
brary using the following criteria: (1) the unique peptides
for a specific targeted protein were ranked by the inten-
sity of the precursor ion from the IDA analysis as esti-
mated by the ProteinPilot™ software; and (2) peptides
that contained biological modifications and/or were
shared between different protein entries/isoforms were
excluded from selection. Up to 15 peptides were chosen
per protein, and SWATH™ quantitation was attempted
for all proteins in the library file that were identified
below 5 % local FDR from ProteinPilot™ searches. In
SWATH™ Acquisition data, peptides are confirmed by
finding and scoring peak groups, which are a set of frag-
ment ions for the peptide. Target fragment ions, up to 5,
were automatically selected and peak groups were
scored following the criteria described in Lambert et al.
[52]. Peak group confidence threshold was determined
based on a FDR analysis using the target-decoy approach
and 1 % extraction FDR threshold was used for all the
analyses. Peptides that met the 1 % FDR threshold inone of the samples were retained, and the peak areas of
the target fragment ions of those peptides were extracted
across the experiments using an extracted-ion chro-
matogram (XIC) window of 3.0 min. The levels of the
human proteins were estimated by summing all the tran-
sitions from all the peptides for a given protein (an
adaptation of [53]) and normalized to the more stable
internal standard.
Statistical analysis
Statistical evaluation was performed using one-way ana-
lysis of variance and Student’s t-test through the pro-
gram GraphPad Prism 5 (GraphPad Software Inc., La
Jolla, CA, USA). Data are presented as mean ± SEM.
The significance value was set at p < 0.05.
Results
Expansion of hWJ-MSCs under normoxic and hypoxic
conditions on Cytodex 3 microcarriers in dynamic conditions
PPRF-msc6 has been shown to support the rapid and
efficient isolation and expansion of human bone marrow
MSCs (hBM-MSCs) from bone marrow mononuclear
cells. Additionally, higher cell yields were obtained in
comparison to hBM-MSCs that were isolated and
expanded in classical serum-based medium over the
same culture period [19, 41]. Moreover, this serum-
free medium was shown to support the isolation and
expansion of hMSCs derived from adipose, pancreatic
and umbilical cord in conventional static culture [54].
Herein, we report that hWJ-MSCs were able to attach
to and grow on Cytodex 3 microcarriers in computer-
controlled stirred suspension bioreactors in normoxic
and hypoxic conditions (Fig. 1a, b). We also set and
controlled key parameters in this dynamic environ-
ment and observed that dissolved oxygen (21 % (nor-
moxic) and 5 % (hypoxic)) was well controlled within
the bioreactor at the set points during the expansion
and conditioning phase as illustrated in Fig. 1c, d. Cell
viability analysis using a Vi-Cell XR Cell Viability
Analyzer (Beckman Coulter, Danvers, MA, USA) re-
vealed a percentage of viable cells above 98 %.
Hypoxic and normoxic hWJ-MSC secretomes induced
neuronal differentiation of hNPCs in vitro
hNPCs were grown as neurospheres in a serum-free
medium (PPRF-h2) [42]. The impact of hWJ-MSC secre-
tomes (from hypoxic and normoxic conditions) on the
differentiation of hNPCs was evaluated. Upon the re-
moval of PPRF-h2, and plating in adherent dishes with
hWJ-MSC normoxic or hypoxic secretomes, hNPCs ad-
hered and started to differentiate. After 5 days incubated
with hWJ-MSC CM, a Vi-Cell XR Cell Viability Analyzer
(Beckman Coulter) was used to verify that the percent of
viable cells during the total time in the CM was
Fig. 1 Expansion and adherence of hWJ-MSCs on Cytodex-3 microcarriers in computer-controlled bioreactors. hWJ-MSCs visualized by staining
with 0.5 % crystal violet in methanol, were able to adhere to microcarriers under a hypoxic and b normoxic conditions in the suspension bioreac-
tors, and were well maintained at predetermined set points for the culture period (c, d). Scale bars: 200 μm
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munocytochemistry analysis revealed that when hNPCs
were incubated for 5 days with the hWJ-MSC CM of both
conditions (normoxic and hypoxic) there was a clear
increase (p < 0.01) in DCX+ positive- (immature neurons;
Fig. 2b, c, g) and MAP-2 positive cell (mature neurons;
Fig. 2e, f, h) densities when compared to the control group
(incubation with Neurobasal-A medium; Fig. 2a, d), sug-
gesting that both secretomes (from normoxic and hypoxic
conditions) favored hNPC differentiation.
Hypoxic and normoxic conditions affect the profile of
hWJ-MSC secretome
In order to further understand the effects of using differ-
ent percentages of oxygen (i.e., normoxic and hypoxic
conditions) on the secretome of hWJ-MSCs, a proteomic-
based analysis was performed. From the results, it was
observed that the use of different oxygen percentagesmodulated the hWJ-MSC secretome to produce a differ-
ent pattern of expression (Fig. 3a, b), in which the hypoxic
preconditioning led to an increased secretion profile of
hWJ-MSCs when compared to the normoxic precondi-
tioning. Indeed, it was possible to identify under normoxic
conditions 104 proteins, whereas under hypoxic condi-
tions 166 proteins were identified in which 81 proteins
were common to the two conditions (Fig. 3c). After this
proteomic analysis identification, when both hWJ-MSC
secretomes were analyzed for specific proteins with
possible neuroregulatory actions on the CNS physi-
ology (including on their derived cells), it was possible
to observe that hWJ-MSCs secreted important mole-
cules. Thymosin-beta (p < 0.01) and EF-2 (p < 0.05)
were found to be significantly upregulated in the hyp-
oxic conditions when compared to the normoxic-
related levels (Fig. 4a, b). On the other hand, for all the
other proteins found (also with neuroregulatory potential),
Fig. 2 In vitro differentiation of hNPCs into immature and mature neurons. hWJ-MSC CM collected from hypoxic (Hypo) and normoxic (Norm)
conditions was able to significantly support and induce neuronal differentiation of hNPCs into b,c immature (DCX+ cells) and e,f mature (Map-2+
cells) neurons when compared to control conditions (a,d). From g,h cell count analysis it was clearly evident the significant increase of DCX+ and
Map-2+ cell densities in both hWJ-MSC CM (from normoxic and hypoxic conditions) when compared to the control group (values are shown as
mean ± SEM. **p < 0.01). Scale bar: 100 μm. CTR control, DAPI 4-6-diamidino-2-phenylindole-dihydrochloride, DCX doublecortin, MAP-2 micro-
tubule associated protein-2
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between the two different conditions (normoxic and
hypoxic) were observed. Regarding normoxic condi-
tions, GDN and Cys C expression were found to be
relatively upregulated when compared to the hypoxic
conditions (Fig. 4c, d). Similar to this, but with a clear
positive trend, UCHL1, clusterin, Prx1 and 14-3-3 were
found to have higher secretion levels when compared
to the normoxic conditions (Fig. 4e–h). In addition to
this, specific proteins that were restricted to each con-
dition were detected, presenting important roles in
CNS regulation. Under normoxic conditions the pres-
ence of vitronectin, cadherin-2 and MRP-1 was identi-
fied whereas, under the hypoxic conditions, PEDF,
IGF-2, semaphorin-7A, MIF, Hsp70 and moesin were
identified.Discussion
Reports have defended the proposition that the stem cell
niche represents and plays an important role in stem cell
biology and fate, in which oxygen concentration is an im-
portant component and regulator [20, 55]. Indeed, it has
been suggested that low levels of oxygen (i.e., hypoxia) play
an important role in the maintenance of the plasticity and
proliferation of stem cells [22]. According to Cicione et al.
[21] and Grant et al. [56] the conventional in vitro cultures
are often carried out under ambient oxygen tension corre-
sponding to 21 %, called the normoxic condition. However,
the in vivo physiologic oxygen concentration is lower than
this, varying from tissue to tissue and ranging from 1 to
13 % [56]. In this way, the use of 21 % oxygen tension
exceeds the normal pressure that exists in most of the
mammalian tissues, which indicates that the oxygen
Fig. 3 (See legend on next page.)
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Fig. 3 hWJ-MSC CM proteomic analysis. Graphical representation of WJ-MSC CM proteomic analysis by mass spectrometry. Peaks detected (from
different donors: WJ1, WJ2, WJ3) after CM analysis show that the patterns of protein expression are modulated when we change from a normoxic
to b hypoxic culture conditions. Indeed, the Venn diagrams (c) indicated that more proteins were identified in the hWJ-MSC CM collected from
hypoxic conditions (166 proteins) when compared to the normoxic hWJ-MSC CM (104 proteins), in which 81 were common to the two
conditions. The color scale shown illustrates the relative expression of the indicated proteins across the samples: red denotes low expression
and green denotes high expression
Teixeira et al. Stem Cell Research & Therapy  (2015) 6:133 Page 9 of 14concentration used during standard in vitro cultures of pri-
mary human cells, like MSCs, does not mimic the in vivo
environment [21, 57]. Additionally, it has been hypothe-
sized that culturing hMSCs under normoxic conditions
could lead to a reduction in their therapeutic potential [58].Fig. 4 Specific hWJ-MSC CM proteins with neuroregulatory potential on CN
the hWJ-MSC CM collected from hypoxic (Hypo: A- thymosin-beta; B- elon
(UCHL1); F- clusterin; G- peroxiredoxin 1 (Prx1) and H- 14-3-3) and normox
with known neuregulatory actions. Values are shown as mean ± SEM, n =First, we showed that the in vitro application of the
hWJ-MSC secretomes obtained from normoxic and
hypoxic conditions revealed that both were able to main-
tain cell viability and induce differentiation of human
CNS-derived cells. As seen in Fig. 2, when hNPCs wereS physiology. Comparative analysis of the secreted paracrine factors in
gation factor 2 (EF-2); E- ubiquitin carboxy-terminal hydrolase L1
ic (Norm: C- glia-derived nexin (GDN); D- cystatin C (Cys C)) conditions
3; *p < 0.05; **p < 0.01. IS internal standard
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lar levels of neuronal differentiation (namely, immature
(DCX+ cells) and mature (Map-2+ cells) neurons), were
observed. This is in line with what Sart and colleagues
[59] have already reported regarding the effects of hyp-
oxic and normoxic hMSC CM on NPC survival, differ-
entiation and maturation. In addition, they also observe
that both CM (from normoxic and hypoxic conditions)
were also able to enhance the proliferation, migration
and neurite outgrowth of NPCs [59]. Factors such as
brain-derived neurotrophic factor (BDNF), nerve growth
factor (NGF), fibroblast growth factor 2 (FGF-2), stem
cell-derived factor 1 alpha (SDF-1α) and transforming
growth factor beta 1 (TGF-β1) secreted by MSCs have
been considered the major players involved in their po-
tential for promoting growth and neural differentiation
of hNPCs [13, 60–62]. Furthermore, it has been hypoth-
esized that hMSC secretome could also be a stimulator
of endogenous extracellular matrix (ECM) proteins se-
cretion by NPCs, acting as a modulator of NPC behavior
by influencing the ratio of adherence and differentiation
[59]. This clearly suggests that the hMSC secretome may
be able to enhance the neural survival and differentiation
of NPCs due to the regulation of the molecular milieu,
including ECM proteins and growth factors [59, 63, 64].
The proteomic analysis performed in the present
work revealed that hWJ-MSCs were able to produce
molecules with neuroregulatory potential other than
those commonly described in the literature, particularly
under hypoxic conditions. Of these, thymosin-beta and
EF-2 were found to be significantly upregulated under
hypoxic conditions when compared to the normoxic
conditions (Fig. 4a, b). To a lesser extent, GDN and
Cys C were found to be upregulated in normoxic con-
ditions (Fig. 4c, d), whereas UCHL1, clusterin, Prx1 and
14-3-3 secretion tended to be higher under hypoxic
conditions (Fig. 4e–h). Together, all these proteins have
been reported to have important roles in neurite out-
growth, inhibition of apoptosis, neuroprotection, antioxi-
dant activities and angiogenic effects [65–72]. For instance,
thymosin-beta (significantly expressed, p < 0.01; Fig. 4a)
and EF-2 (significantly expressed; p < 0.05; Fig. 4b)
have been associated with important roles in the regu-
lation of neurite outgrowth as well as neuroprotective
actions in Alzheimer's disease [71–74]. GDN and Cys C
(Fig. 4c, d) are known to play crucial roles in the enhance-
ment of neurite outgrowth and neuroprotection through
the prevention of oxidative stress [65, 75–78]. On the
other hand, UCHL1 and clusterin (Fig. 4e, f ) have been
described as important enhancers of neuroprotection and
neurogenesis (e.g., neuronal process formation, elong-
ation, and plasticity) as well as a potential target into
some neurodegenerative disorders such as Alzheimer’s
disease [67, 79–82]. Finally, Prx1 and 14-3-3 (Fig. 4g, h)are known for their important roles on regeneration,
cell migration, and axonal growth, as well as for neurite
outgrowth and neuroprotection [45, 68, 69, 83, 84].
Interestingly, in addition to this, we have also discov-
ered specific proteins that were only detected in each
condition. From these, vitronectin, cadherin 2 and
MRP1 (only present in the normoxic hWJ-MSC CM)
have been described as important modulators of neur-
onal differentiation, axonal growth and neuroprotection
[85–90]. On the other hand, PEDF, IGF-2, semaphorin-
7A, MIF, Hsp70 and moesin (only present in the hyp-
oxic hWJ-MSC CM) are known for their roles in the en-
hancement of neuroprotection, axonal growth, neurite
outgrowth and neuronal cell survival and differentiation
[90–99]. Interestingly, previous results from our group
have identified the presence of some of these proteins,
such as UCHL1, 14-3-3 and Hsp70, that were correlated
with an increase in neuronal cell densities in cortical
and cerebellar primary cultures [45].
Like Sart and colleagues [59], we have also observed
that the hypoxic CM displayed similar cellular responses
on hNPC differentiation when compared to normoxic
conditions. This was surprising as the proteomic analysis
revealed that there was a robust increase in most of the
proteins referred to above for the secretome collected
under hypoxic conditions. We believe that this could in-
dicate that the differences in concentrations of the pro-
teins that were detected may not be sufficient to induce
significant variation in the functional differentiation of
hNPCs. Similar outcomes were also presented by the
other authors who observed that hypoxic conditions
could increase the secretory profile of MSCs (increasing
the levels of FGF-2, BDNF and VEGF) when compared
to normoxic conditions. However, the dose/level ob-
tained may not be sufficient to elicit differences in cell
adhesion/proliferation/differentiation of NPCs when
compared to the normoxic conditions [59]. The collec-
tion time of the hMSC secretome might be one of the
reasons that could limit its effects on hNPC differenti-
ation, as it has already been demonstrated that the
time of conditioning affects the hMSC secretome pro-
tein profile even under hypoxic conditions [100, 101].
In addition to this, the oxygen tension could be an-
other important issue. In fact, as recently demon-
strated by Hsiao and colleagues [100], the paracrine
profile of MSC-like cells may be dependent on the
oxygen concentration. Nevertheless, it was evident that
a dynamic culturing environment, such as the use of
hypoxic conditions, leads to significant changes in the
composition of the hWJ-MSC secretome. Although the
mechanisms responsible for these changes are still not
fully understood, studies have suggested that one of the
mechanisms by which MSCs respond to oxygen tension is
through transcription factors, namely the hypoxia-
Teixeira et al. Stem Cell Research & Therapy  (2015) 6:133 Page 11 of 14inducible factors HIF-1α and HIF-2α [20, 22]. These
factors are degraded under normoxic conditions, but
stabilized under hypoxic conditions, playing essential roles
in a variety of cellular and molecular mechanisms of
MSCs [21, 102, 103]. In addition to this, it was also dem-
onstrated that proangiogenic factor production (e.g., IL-6
and VEGF) by MSCs was increased under hypoxic pre-
conditioning, assuming that these beneficial effects might
be also regulated by a complex array of signaling pathways
such as the Akt and ERK pathways [104–107]. Taking all
this into consideration, future standardized experiments
should be developed in order to analyze the use of
different hypoxic oxygen concentrations (for instance,
below 5 %) and compared to the normoxic state, in
order to get an insight of the real action of low levels of
oxygen on the hMSC secretome physiology.
Conclusions
In the present work, we have demonstrated that the
secretomes of hWJ-MSCs collected from normoxic and
hypoxic conditions were able to induce neuronal differ-
entiation of hNPCs into neurons in different stages of
maturation. These outcomes were associated with the
presence of important neuroregulatory molecules within
the constitution of the secretomes such as GDN, Cys C,
UCHL1, clusterin, Prx1, 14-3-3, thymosin-beta and EF-
2. These are important molecules involved in the pro-
motion of neuroprotection, inhibition of apoptosis,
angiogenesis and neuronal cell survival and differenti-
ation. Thus, our results suggest that the use of hypoxic
preconditioning enhances the hWJ-MSC secretome when
compared to the normoxic precondition, indicating that
hWJ-MSCs differ in their sensitivity when exposed to
different oxygen concentrations, which may allow the
development of new therapeutic strategies in the future.
However, with conditions tested in the present study
there were no changes in the neuroregulatory (neural
differentiation) profile of the secretome. In the future,
different hypoxia oxygen concentrations should be
tested in order to identify the optimal parameters for
enriching the WJ-MSC secretome under a dynamic and
hypoxic environment.
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